Conditionally replicating adenoviruses (CRADs) take advantage of tumor-specific characteristics for preferential replication and subsequent oncolysis of cancer cells. The antitumor effect is determined by the capability to infect tumor cells. Here, we used RGDCRADcox-2R, which features the cyclooxygenase-2 promoter for replication control and an integrin binding RGD-4C motif for enhanced infectivity of ovarian cancer cells. RGDCRADcox-2R replicated in and killed human ovarian cancer cells effectively, while the replication in nonmalignant cells was low. Importantly, the therapeutic efficacy, as evaluated in an orthotopic model of peritoneally disseminated ovarian cancer, was significantly improved and toxicity was lower than with a wild-type virus. Thus, this CRAD could be tested for treatment of ovarian cancer in humans.
Introduction
Adenovirus (Ad)-mediated gene therapy has been proposed as a treatment alternative for advanced cancers refractory to conventional therapies. Ads are attractive vectors for cancer due to their unparalleled capacity for gene transfer, stability in vivo and the feasibility of high titer production. However, currently there is little evidence supporting significant clinical benefits. 1 This might be due to inefficient transduction of solid tumor masses with replication-deficient Ad-vectors. To help overcome this obstacle, selectively oncolytic agents, that is, conditionally replicating adenoviruses (CRADs), have been constructed. Infection of tumor cells results in replication, oncolysis and subsequent release of the virus progeny. Normal tissue is spared due to lack of replication, which can be achieved by two strategies. Type 1 CRADs have a partial deletion in the immediately-early (E1A) or early (E1B) adenoviral genes resulting in a mutant E1 protein unable to bind cellular proteins necessary for viral cell cycle in normal cells, but not in cancer cells. Another strategy is the control of viral replication with various heterologous tumor/tissuespecific promoters, TSPs. 2, 3 We constructed a CRAD containing the cyclooxygenase-2 (cox-2) promoter for controlling expression of E1A. 4 The expression cassette is inverted to minimize the influence by the left inverted terminal sequences and packaging signal. Cox-2 has been shown to be highly expressed in a number of epithelial tumors, including ovarian carcinoma. Furthermore, it is closely linked to carcinogenesis and progression of epithelial tumors. 5 There are studies suggesting increased cox-2 gene expression after infection with various pathogens. [6] [7] [8] However, with regard to Ad, this has not been studied. Also, an Ad featuring the cox-2 promoter has displayed specific transgene expression in cox-2-positive cancer cells, while the expression in liver and mesothelial cells was low. [9] [10] [11] Recently, it has been demonstrated that the oncolytic potency of replicating agents is directly determined by their capability to infect target cells. 12 Unfortunately, it has also been shown that expression of the Ad primary receptor, coxsackieadenovirus receptor (CAR), is highly variable and often low on various tumor types, including ovarian cancer (reviewed in Bauerschmitz et al . Further, there may be an inverse correlation between CAR expression and tumor grade. 13 Thus, low CAR levels may hinder CRADmediated oncolysis. Therefore, methods to circumvent CAR-deficiency and improve cell killing have been evaluated in the context of CRADs. The concept has been validated by incorporation of an arginine-glycineaspartic acid (RGD-4C) modification into the HI-loop of the fiber of a type 1 CRAD (Ad5-D24RGD).
14 Subsequently, we studied the replication and oncolytic potency of this agent on ovarian cancer substrates. 15 For the purpose of clinical testing with ovarian cancer patients, we have attempted to identify the best available infectivity enhanced CRAD. An RGD-4C-modified cox-2-based CRAD (RGDCRADcox-2R) was constructed and compared to Ad5-D24RGD, which has displayed preclinical efficacy in ovarian cancer. Another control was a wild-type Ad5, which may be a useful control for optimal replication.
Results

RGDCRADcox-2R kills ovarian cancer cells in vitro
Monolayers of SKOV3.ip1, OV-3, OV-4, ES-2 and Hey were infected with RGDCRADcox-2R, Ad5-D24RGD, Ad300wt or Ad5lucRGD (Figure 1 ). In all cell lines, the crystal violet staining-based cell killing assay showed almost total oncolysis with Ad5-D24RGD (Figure 1a -e). RGDCRADcox-2R caused greater (SKOV3.ip1) or similar (OV-3, OV-4, ES-2) cell killing as Ad300wt (Figure 1a-d) .
Only in Hey cells did RGDCRADcox-2R show no oncolysis ( Figure 1e ). Ad5lucRGD was included as an E1-deleted control, and it did not cause oncolysis. Another approach for assessing cellular viability is analysis of tumor cell mitochondrial activity by MTS assay (Figure 1f-j) . This quantitative cell killing confirmed the crystal violet findings in three out of five cell lines, while in OV-4 and ES-2 cell viability measured with MTS assay remained high after infection with Ad300wt and RGDCRADcox-2R (Figure 1h, j) . On SKOV3.ip1 and OV-3 cells, oncolysis was statistically significant with RGDCRADcox-2R in comparison to Ad5lucRGD (P¼0.0054 and Po0.0001, respectively). Further, RGDCRADcox-2R killed more SKOV3.ip1 cells RGDCRADcox-2R displays cox-2 expressiondependent oncolysis and low cell killing of nonmalignant mesothelial cells
To demonstrate cox-2-specific oncolysis, cox-2-positive A549 9 and -negative BT474 4 cell lines were analyzed for cell killing. With A549 cells, RGDCRADcox-2R caused oncolysis comparable to Ad5-D24RGD and Ad300wt when assessed with crystal violet staining (Figure 2a ). In the MTS assay at the highest viral dose, cell viability was 22, 5.9 and 0% with RGDCRADcox-2R, Ad5-D24RGD and Ad300wt, respectively (Figure 2b ), and oncolysis with RGDCRADcox-2R was statistically significant compared to Ad5lucRGD (Po0.0001). RGDCRADcox-2R did not kill in BT474 cells (cell viability 82%), and the difference to Ad5lucRGD was not significant (P¼0.3921), while other replicating Ads displayed oncolysis ( Figure  2c, d ). Cell viability was 12 and 0.2% with Ad5-D24RGD and Ad300wt, respectively (versus RGDCRADcox-2R, 0.0037 and 0.0002, respectively).
Human mesothelial cell line AG07086A and two primary mesothelial cell samples purified from peritoneal strips were analyzed by MTS assay (Figure 2e-g ). At 10 viral particles (vp)/cell, the percentage of viable cells with Ad300wt was 39, 21 and 2.2%, respectively, as compared to uninfected wells. With Ad5-D24RGD, viability was 24, 60 and 15%, and with RGDCRADcox-2R 104, 126 and 42%, respectively. In patient sample 2, RGDCRADcox-2R did not display any cell killing at 1 vp/cell (112%), while Ad300wt and Ad5-D24RGD caused cell lysis (5.8 and 76% viability, respectively) ( Figure 2g ). Importantly, cell killing with RGDCRADcox-2R was not significantly different from the replicationdeficient Ad5lucRGD in the three nonmalignant cell samples (P¼0.5266, 0.5323, 0.0572, respectively), while the other replicating agents killed these nonmalignant cells more than RGDCRADcox-2R (all P-values o0.0270).
RGDCRADcox-2R copy number in ovarian cancer primary cell spheroids 16 were calculated as a sum of all previous time points. (Figure 3e-h ). RGDCRADcox-2R produced 193-, 30-, 8.8-and 1.1-fold more virus than Ad5lucRGD (patients 1-4, respectively). Ad5-D24RGD showed 398-, 30-, 13-and 0.7-fold total virus production compared to Ad5lucRGD. Ad300wt achieved 361-, 31-, 32-and 3.0-fold higher virus DNA production than Ad5lucRGD.
RGDCRADcox-2R in an orthotopic murine model of peritoneally disseminated ovarian cancer
Advanced carcinomatosis was allowed to develop for 10 days and then mice were treated for three consecutive days with RGDCRADcox-2R, Ad5-D24RGD, Ad300wt, Ad5lucRGD or no virus (Figure 4a ). For RGDCRADcox-2R, Ad5-D24RGD, Ad300wt, Ad5lucRGD and no virus, the median survivals of mice were 107, 106, 23, 35 and 37 days, respectively. In pairwise comparisons, survival with RGDCRADcox-2R was significantly enhanced when compared to Ad300wt, Ad5lucRGD or no virus (all Po0.0001). Survival of the mice treated with RGDCRADcox-2R versus Ad5-D24RGD was not significantly different (P¼0.9148).
A higher dose divided into two injections on two consecutive days was also tested (Figure 4b ). For RGDCRADcox-2R, Ad5-D24RGD, Ad300wt, Ad5lucRGD and no virus, the median survivals of mice were 78, 109, 73, 35 and 37 days, respectively. Pairwise w 2 testing confirmed significantly improved survival with RGDCRADcox-2R compared to Ad5lucRGD or no virus (both P o 0.0001). Interestingly, the survival of mice Mice treated with the wild-type serotype 5 strain Ad300wt displayed early mortality, especially with the triple injection schema (Figure 4a ). Necropsy of these mice did not reveal large tumor load or ascites. Interestingly, the livers were abnormal in visual inspection and thus virus copy number was measured. High amounts of virus were detected in the livers of prematurely dead mice (Figure 4c) . When compared to livers of mice injected with a much higher dose of Ad5luc1 (a replication-deficient virus with an identical capsid) the level of virus copies was two orders of magnitude higher (Figure 4c) . Furthermore, histopathology of these livers was analyzed showing massive hepatic necrosis, acute and chronic inflammation and vascular leakage, while the liver of Ad5luc1 was within normal limits ( Figure  4d ).
Discussion
Gene therapy strategies with viral vectors have shown promise in preclinical studies, but inefficient tumor transduction in clinical trials may have limited their clinical efficacy heretofore. Therefore, CRADs have been developed to address this limitation. In this study, we evaluated the efficacy of a CRAD utilizing the cox-2 promoter for controlling E1A expression. Cox-2 is the rate-limiting enzyme in prostaglandin synthesis, and it is involved in control of inflammatory reactions. In most tissues, the activity of cox-2 promoter is low, unless it is induced by growth factors, cytokines or tumor-specific factors. Recently, it has been shown that cox-2 is expressed in many epithelial cancers, and it is related to carcinogenesis and tumor angiogenesis. 5 Expression of cox-2 in ovarian cancer cell lines and, more importantly, in patient tumor specimens has been demonstrated. 17 Further, malignant ascite samples of ovarian cancer patients often feature increased levels of prostaglandin E 2 , suggesting activation of the cox-2 promoter. 17 The cox-2 promoter retains its fidelity in Ad vectors, 9 and is activated in ovarian cancer cell lines and primary cancer cells. 10, 11 Furthermore, its activity is low in the liver, 9 which is important from a safety standpoint. As the efficacy of replicating agents is determined by their infectivity, endeavors to circumvent the frequent deficiency of CAR on clinical cancers have been evaluated. One method is genetic modification of the fiber knob with an RGD-4C motif, which allows binding to a v b integrins, which are regularly expressed and often overexpressed on tumor vasculature and ovarian cancer cells. 18, 19 RGD-4C-modified Ads have been shown to achieve enhanced gene expression in and therapeutic efficacy with low-CAR targets, including ovarian cancer. [18] [19] [20] A further advantage of this tropism modification is reduced neutralization by pre-existing neutralizing anti-adenovirus antibodies. 19, 20 This could be important, as most ovarian cancer patients have malignant ascites containing such antibodies, which could compromise initial infection of tumor cells and spreading of new Therefore, early mortality in the Ad300wt group was probably due to constant high level virus production in the tumors, vascular dissemination and subsequent uptake by the liver.
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A Kanerva et al virions. 19, 21 With regard to preclinical assessment of biodistribution and toxicity, preliminary results suggest that the RGD-4C modification does not affect either aspect adversely, when virus is administered i.p. to mice with ovarian carcinomatosis. 20 Here, we performed a preclinical evaluation of RGDCRADcox-2R in the context of ovarian cancer. It was also compared to a type 1 CRAD, Ad5-D24RGD, which has shown preclinical efficacy 15 and is now undergoing clinical evaluation. Ad5-D24RGD contains a 24-bp deletion in the E1A, in the area of the E1A protein responsible for binding retinoblastoma protein. This binding normally allows Ad to induce S-phase entry, needed for virus replication. Therefore, Ad5-D24RGD replicates only in cells inactive in their Rb/p16 pathway, which includes most human cancers. 22 We evaluated the cell killing efficacy of RGDCRADcox-2R in five ovarian adenocarcinoma cells lines, which are shown to express cox-2 or allow cox-2-controlled transgene expression. 10, 11, 17 In a crystal violet staining assay, RGDCRADcox-2R displayed similar or enhanced oncolysis when compared to a wild-type Ad, while Ad5-D24RGD achieved almost total oncolysis with all cell lines (Figure 1a-e) . In a quantitative cell killing assay, the efficacy of RGDCRADcox-2R was slightly lower. In general, cell killing correlated very well with cox-2 expression. One analyzed ovarian cancer cell line, Hey, did not display oncolysis with RGDCRADcox-2R ( Figure  1e, j) , although it allows cox-2-mediated gene expression. 11 This cell line grows very fast, which may compensate for the cell lysis induced by RGDCRADcox-2R replication. Importantly, RGDCRADcox-2R caused only minimal lysis of non-malignant mesothelial cells, while the wild-type Ad and Ad5-D24RGD achieved significant cell killing (Figure 2 ). This suggests that the cox-2 promoter retains its fidelity in a CRAD context, as has been shown earlier with E1-deleted viruses.
9,10 Taken together with the earlier report of low liver toxicity, 4 this could represent an important safety feature, as all published ovarian cancer trials have utilized i.p. admininstration. RGDCRADcox-2R replicated in ovarian cancer primary cell spheroids to a level comparable to wild-type Ad (Figure 3) . Replication of Ad5lucRGD DNA in patient sample 4 might be due to 'E1A-like' activity, a previously reported phenomenon present in many cancer cells, which allows replication of Ad vector DNA in the absence of E1A. 16, 23 Finally, the therapeutic efficacy of the agent was evaluated in an orthotopic animal model of ovarian cancer (Figure 4 ). Both CRADs displayed significantly enhanced survival in comparison to controls. Although Ad5-D24RGD was more oncolytic in vitro, there was no significant difference between these CRADs in vivo. However, the systems analyzed are different, in vitro most viral particles are expected to enter and exit cells, while in vivo there are tissue barriers and other factors associated with the three-dimensional structure of normal organs and cancer tissues. As compared to CRADs, mice treated with wild-type Ad experienced early morbidity and mortality, which was most prominent ca. 7 days after virus injection. Livers were harvested, and they displayed massive hepatic necrosis and high amounts of viral DNA suggesting virus replication, dissemination and subsequent liver uptake and toxicity as the cause of death. The appearance of symptoms approximately 1 week after virus administration suggests that virus replication proceeded effectively in the tumor tissue, virions disseminated into the bloodstream and finally were sequestered in the liver, which eventually failed. Interestingly, no such toxicity was seen for the RGD-4C-modified CRADs. More in-depth studies are needed, but perhaps the RGD-4C-modification allowed more effective entry into tumor cells and thus less viral circulation. Further, although human Ads do not effectively replicate in mice, perhaps the degree of Ad early gene expression may, nevertheless, affect mouse toxicity. Conceivably, RGDCRADcox-2R and Ad5-D24RGD would have reduced production of E1A due to low cox-2 activity and an intact Rb/p16 pathway, respectively.
In conclusion, we have demonstrated that RGDCRADcox-2R allows tumor-specific replication and cell killing comparable to wild-type Ad. Thus, RGDCRADcox-2R could be an effective agent for treatment of ovarian cancer, and other tumors expressing cox-2. If proven safe in clinical studies, RGDCRADcox-2R could be useful for treatment of other tumors featuring high expression of cox-2 and low expression of CAR. In some in vitro experiments, this agent was less oncolytic than Ad5-D24RGD. However, RGDCRADcox-2R also caused less toxicity to nonmalignant cells. Clinical trials may ultimately determine if these features are retained in humans and which is more important -specificity or efficacy. We feel that both Ad5-D24RGD and RGDCRADcox-2R are promising agents, and both agents have potential benefits. The distinct approaches for regulation of replication could be useful for avoiding potential resistant clones if patients were treated with alternating cycles of the agents. Primary mesothelial cells were obtained by enzymatic disaggregation of fresh peritoneal strips collected from female patients undergoing intra-abdominal surgery. 20 Primary ovarian adenocarcinoma cells were purified with a previously described immunomagneticbased method 24 from the malignant ascites fluid of patients undergoing a procedure for ovarian cancer. To create three-dimensional spheroids, cells were suspended in growth medium in 3% agar coated flasks. 
Materials and Methods
Cells and tissues
Cell killing assays
Cells were infected with RGDCRADcox-2R, Ad5-D24RGD, Ad300wt or Ad5lucRGD as reported. 25 Briefly, MTS assay was performed on 96-well plates, and viruses were diluted in 50 ml of 2% growth medium. For crystal violet staining, cells were plated and infected on six-well plates, and infection volume was 500 ml. Utilizing crystal violet staining 15 or MTS assay, 25 oncolysis was evaluated when RGDCRADcox-2R or Ad300wt showed clear oncolysis with lowest amount of virus. The results with RGDCRADcox-2R were compared to the other groups using a two-tailed t-test (SAS, v.8.2, SAS Institute, Cary, NY, USA).
Quantitating virus replication
Primary ovarian cancer cells were purified and cultured as spheroids overnight. The next day, spheroids were infected with 1000 vp/surface cell of RGDCRADcox-2R, Ad5-D24RGD, Ad300wt, Ad5lucRGD, or no virus. Then, the spheroids were divided into aliquots of 10 5 cells in Costar s 96-well ultra low attachment plates (Corning Inc., Corning, NY, USA). Cells and growth medium were harvested together and frozen at 0.5, 1, 2, 4, 6, 8, 12 and 16 days after infection (days 2-20 from patient 4). Purification of DNA and quantitative PCR for the E4 were performed as described. 25 
Therapeutic ovarian cancer model
Female CB17 SCID mice (UAB CFAR SCID Mouse Core Facility) were obtained at 3-4 weeks of age and quarantined for 2 weeks. Mice were kept under pathogen-free conditions according to the American Association for Accreditation of Laboratory Animal Care guidelines. Animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of UAB. On day 0, mice were injected i.p. with 1x10 7 SKOV3.ip1 cells. On days 10, 11 and 12, mice were injected i.p. with 1 Â 10 8 vp of RGDCRADcox-2R (n¼9 mice), Ad5-D24RGD (n¼9), Ad300wt (n¼9), Ad5-lucRGD (n¼7), or no virus (n¼6) in 1 ml of Opti-MEM (Mediatech, Herndon, VA, USA). In another experiment, mice were injected i.p. on days 10 and 11 with 5 x 10 9 vp of RGDCRADcox-2R (n¼9 mice), Ad5-D24RGD (n¼8), Ad300wt (n¼9), Ad5lucRGD (n¼7) or no virus (n¼6) in 1 ml of Opti-MEM. Mice were followed daily and killed when there was any evidence of pain or distress. Survival data were plotted on a Kaplan-Meier curve, and the RGDCRADcox-2R group was compared with the other groups with the w 2 test (LIFETEST procedure in SAS v.8.2). The livers of mice that died early after treatment with Ad300wt were harvested on day 19 and fixed in 10% neutral buffered formalin. Serial paraffinembedded sections were prepared and stained with hematoxylin and eosin (H&E). Histopathology was examined in a blinded fashion by two independent pathologists. Liver DNA was purified and E4 copy number was analyzed as above. Data were obtained also with Ad5luc1, an E1/E3-deleted Ad with a wild-type fiber, using a single injection of 5 Â 10 10 vp.
